Evolus, Inc.
No SEC Form 4 filings for $EOLS in the last 30 days.
See all $EOLS insider activity →Evolus Inc. (EOLS) has entered an option agreement with a private company to develop an injectable hair restoration treatment. The company will pay $1.5 million upfront and support development, with an option to acquire the program. Clinical trials are expected to start after 2027. Shares of Evolus were down 2.5% to $7.32.
Evolus (EOLS) shares dropped after the FDA issued a warning about an Instagram post promoting its Jeuveau product, stating it misleads consumers and may violate federal law. The post was removed following the warning. The FDA's action highlights regulatory risks for pharmaceutical marketing on social media.
Evolus (EOLS) reported Q2 2026 revenue of $84.1M, up 21% YoY, and positive Adjusted EBITDA of $4.7M. The company raised full-year revenue guidance to $330M-$337M and adjusted gross profit margin guidance to 67.0%-67.5%. Evolus expanded its customer base and loyalty program, while investing in new product launches and partnerships.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning EOLS (Evolus, Inc.). Coverage has skewed bearish: 0 bullish, 3 neutral, and 1 bearish.
Recent EOLS coverage spans financial news, earnings and regulation.
Shares fell 2.5% on the news, reflecting modest downside pressure as investors weigh the cost and early‑stage nature of the program.
Negative regulatory scrutiny likely pressures the share price.
Profitability milestone and higher guidance may boost investor sentiment.
Revenue growth and narrowing losses suggest improving fundamentals.
The insider sale may signal weak confidence, potentially pressuring the stock short-term.
AlphAI scores every news story that mentions EOLS with an AI model for sentiment and relevance, and aggregates insider trades from Evolus, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Evolus Inc. (EOLS) has entered an option agreement with a private company to develop an injectable hair restoration treatment. The company will pay $1.5 million upfront and support development, with an option to acquire the program. Clinical trials are expected to start after 2027. Shares of Evolus were down 2.5% to $7.32.
1 min readEvolus (EOLS) shares dropped after the FDA issued a warning about an Instagram post promoting its Jeuveau product, stating it misleads consumers and may violate federal law. The post was removed following the warning. The FDA's action highlights regulatory risks for pharmaceutical marketing on social media.
1 min readEvolus (EOLS) reported Q2 2026 revenue of $84.1M, up 21% YoY, and positive Adjusted EBITDA of $4.7M. The company raised full-year revenue guidance to $330M-$337M and adjusted gross profit margin guidance to 67.0%-67.5%. Evolus expanded its customer base and loyalty program, while investing in new product launches and partnerships.
2 min readPro-Dex (PDEX) rose 18% to $77 on FY'26 results, with net sales up 16% to $77.5M. Odyssey (ODTX) gained 8% to $29.05, reporting a Q2 loss of $52.8M. Evolus (EOLS) climbed 2% to $9.31, with Q2 revenue up 21% to $84.1M. Biofrontera (BFRI) increased 6% to $1.63, with Q2 product revenue up 32.9%. Alpha Tau (DRTS) hit $15.17, reporting a Q2 loss of $68.8M.
2 min readMOATAZEDI DAVID (See Remarks) sold 105,108 shares of Evolus, Inc. (EOLS) at $9.04 ($0.95M total) on 2026-09-02.
1 min readRenovoRx (RNXT) rose 15% to $1.97 on positive Phase 3 trial data. Evolus (EOLS) hit $9.15 after 21% revenue growth. Crinetics (CRNX) reached $85.01 ahead of $10B Vertex (VRTX) acquisition. Apogee (APGE) hit $135.08 before $10.9B AbbVie (ABBV) deal. All hit 52-week highs on August 31, 2026.
3 min readEvolus, Inc. (EOLS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook • Global Net Revenue of $84.1 Million for the Second Quarter of 2026, an Increase of 21% Over the Prior Year, Re
4 min readEvolus said it expanded its partnership with Symatese to commercialize the Estyme injectable hyaluronic acid gel collection in Canada, Australia, and New Zealand. The deal, first announced in 2023, is expected to begin commercialization in 2028. Evolus also said it will hold exclusive rights in markets where it sells Jeuveau and Nuceiva. Shares were about $6.04.
2 min readEvolus, Inc. (EOLS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme ® in Canada, Australia, and New Zealand Establishes a complementary injectable hyaluronic acid (HA) gel portfolio alongside Jeuveau ® and Nuceiva ® across all Evolus commercial markets Further leverages Ev
4 min readEvolus Inc. said it signed an exclusive licensing and distribution deal with Swiss firm IBSA to develop and commercialize Profhilo in the U.S. Evolus will manage U.S. regulatory development and commercialization after approval. Profhilo is an injectable skin treatment launched in Europe in 2015 that stimulates collagen. Evolus shares were about $6.90.
2 min read
